Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImPrEP CAB: Implementation of Long-acting Injectable Cabotegravir for HIV PrEP
NCT05515770Phase 3Recruiting
- Sponsor
- Evandro Chagas National Institute of Infectology
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by Evandro Chagas National Institute of Infectology. Started Sep 2022; status: recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05515770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515770.